Related references
Note: Only part of the references are listed.
Review
Urology & Nephrology
Sara S. Jdiaa et al.
Summary: This review focuses on the impact of Chronic Kidney Disease (CKD) on the poor outcomes of COVID-19 and highlights the importance of identifying strategies to prevent COVID-19 infection among patients with CKD.
JOURNAL OF NEPHROLOGY
(2022)
Article
Urology & Nephrology
Maxime Espi et al.
Summary: The level of protection provided by two doses of COVID-19 mRNA vaccines in patients receiving maintenance hemodialysis (MHD) is uncertain. This study found that vaccination significantly reduced the incidence and severity of COVID-19, but 11% of patients infected after two doses still died. Lack of protection in SARS-CoV-2-naive patients could be due to defective T-cell response and failure to generate sufficient neutralizing antibodies after vaccination. Administering a third dose of vaccine improved protection in low/no responders. High responders did not show an increase in antibodies after the third dose but experienced more side effects. The antibody and T-cell response after two doses can guide personalized administration of the third dose in MHD patients.
KIDNEY INTERNATIONAL
(2022)
Review
Immunology
Paul Moss
Summary: T cell immunity plays a central role in controlling SARS-CoV-2 infection, with early responses correlating with protection. T cell memory provides broad recognition of viral proteins, limiting the impact of viral variants and offering protection against severe disease. Current COVID-19 vaccines elicit robust T cell responses, contributing to the prevention of hospitalization or death. Therefore, the importance of T cell immunity may have been underestimated.
Article
Transplantation
Niko Kohmer et al.
Summary: The efficacy of a booster dose of mRNA-1273 was determined in dialysis patients who had previously received two doses of BNT162b2. The results showed that the booster dose significantly increased the level of SARS-CoV-2 spike antibodies in almost all patients, providing virus-neutralizing quantities of antibodies.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2022)
Article
Medicine, General & Internal
Leena Taji et al.
Summary: Patients undergoing long-term dialysis are at higher risk of SARS-CoV-2 infection and death, particularly if they receive in-center hemodialysis, reside in long-term care facilities, live in the Greater Toronto Area, belong to Black or Indian subcontinent ethnicities, have lower income levels. These patients should be prioritized for vaccination and special attention should be paid to addressing risk factors for infection.
CANADIAN MEDICAL ASSOCIATION JOURNAL
(2021)
Article
Immunology
Claudius Speer et al.
Summary: Patients undergoing hemo- or peritoneal dialysis show lower levels of antibodies after vaccination compared to healthy individuals, with a significant decrease observed after the second dose. Boosters may be necessary for high-risk individuals with impaired seroconversion or declining neutralizing antibody levels.
Article
Urology & Nephrology
Eric D. Weinhandl et al.
Summary: Reports from around the world have shown that the fatality rate of patients with COVID-19 among those with ESKD is around 20%-30%. Studies in the United States have indicated that the outcomes of ESKD patients were greatly impacted by COVID-19 in the first half of 2020, with clear racial and ethnic disparities observed, which should be taken into account in prioritizing COVID-19 vaccination distribution.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2021)
Article
Transplantation
Benedikt Simon et al.
Summary: HD patients had significantly lower anti-SARS-CoV-2 S antibody titres compared to controls 21 days after vaccination. The HD group experienced fewer adverse events than the control group. There was no correlation between the antibody response to Hepatitis B vaccination and the SARS-CoV-2 vaccine.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2021)
Article
Medicine, General & Internal
Niko Kohmer et al.
Summary: The PRNT and alternative detection methods show differences in clinical performance and laboratory safety conditions, with high sensitivity and specificity for clinical samples.
JOURNAL OF CLINICAL MEDICINE
(2021)
Letter
Urology & Nephrology
Didier Ducloux et al.
KIDNEY INTERNATIONAL
(2021)
Article
Multidisciplinary Sciences
Ugur Sahin et al.
Summary: The BNT162b2 vaccine shows 95% efficacy in preventing COVID-19 by boosting neutralizing antibody titres and activating specific T cell responses. The vaccine-induced immune response is broad and stable, lasting for a prolonged period, providing good coverage against various SARS-CoV-2 variants.
Article
Medicine, Research & Experimental
Shirin Kalimuddin et al.
Summary: The study showed that spike-specific T cells and binding antibodies were detectable 10 days after the first dose of the Pfizer/Bio-NTech BNT162b2 vaccine, suggesting that early T cell and binding antibody responses may induce early protection against COVID-19 compared to receptor blocking or virus neutralizing activity.
Review
Biochemistry & Molecular Biology
Vincenzo Losappio et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2020)
Article
Multidisciplinary Sciences
Ugur Sahin et al.
Article
Transplantation
Luuk B. Hilbrands et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2020)
Article
Immunology
Li-Ping Wu et al.
EMERGING INFECTIOUS DISEASES
(2007)